查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612801

心臟标记物市场：按产品类型、生物标记物类型、最终用户、适应症分类 - 全球预测 2025-2030

Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年心臟标记市场价值为38.1亿美元，预计到2024年将达到41.6亿美元，复合年增长率为9.71%，到2030年将达到72.9亿美元。

心臟标记是当心臟受损或受压时释放到血液中的生物分子，对于心臟病的诊断和治疗至关重要。对心臟标记的需求源于它们在心血管疾病的早期诊断和及时干预中的重要作用，心血管疾病仍然是全世界死亡的主要原因。这些标记有助于对心肌梗塞和心臟衰竭等疾病进行有效的风险分层、监测和管理。这些标记物通常用于医院急诊室、心臟护理单位和诊断实验室。最终用途多种多样，包括医院、诊断实验室、门诊医疗中心和研究机构。市场成长受到心血管疾病日益普及、生物标记技术进步以及公众对预防性医疗保健意识不断提高的影响。向即时检测和精准医疗的转变带来了巨大的机会，特别是在医疗保健投资不断增加的新兴市场。为了利用这些机会，公司应该专注于开发快速、准确的检测套组，并整合人工智慧以增强资料解释。然而，市场成长受到监管复杂性、先进生物标记测试高成本以及实验室之间缺乏标准化通讯协定的挑战。将基因分析与生物标记分析相结合以及透过巨量资料和机器学习扩大生物标誌物发现等领域的创新将有助于推动业务成长。公司也应该探索与高科技公司合作开发自动化测试解决方案。市场的本质是动态的，由于持续的技术进步，诊断能力不断进步，竞争水平也很高。行业相关人员正在投资研究和开发，建立策略伙伴关係，并使诊断解决方案具有成本效益，以保持竞争优势并满足对改进心臟标记测试不断增长的需求。

主要市场统计
基准年[2023] 38.1亿美元
预测年份 [2024] 41.6亿美元
预测年份 [2030] 72.9亿美元
复合年增长率（%） 9.71%

市场动态：揭示快速发展的心臟标记市场的关键市场洞察

供需的动态交互作用正在改变心臟标记市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 心血管疾病增加
    • 轻鬆取得各种心臟生物标记试剂和套件
    • 改善各国的医疗基础设施和支出
  • 市场限制因素
    • 与心血管手术和解决方案相关的高价格
  • 市场机会
    • 心臟标记的持续进步
    • 持续改善照护现场诊断解决方案的性质
  • 市场挑战
    • 心臟标誌物的严格法规和核准

波特五力：驾驭心臟标记物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解心臟标记物市场的外部影响

外部宏观环境因素在塑造心臟标记市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解心臟标记物市场的竞争状况

心臟标记物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵心臟标记市场供应商的绩效评估

FPNV定位矩阵是评估心臟标记市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和推荐的心臟标记市场，以规划成功之路

心臟标记物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病发生率增加
      • 获得各种心臟生物标记试剂和试剂套件
      • 改善国家医疗基础设施和支出
    • 抑制因素
      • 与心血管手术和治疗相关的高价格
    • 机会
      • 心臟标记的持续进步
      • 不断改进照护现场的性质
    • 任务
      • 心臟标誌物的严格法规和核准
  • 市场区隔分析
    • 产品：提供心臟特异性蛋白质定性和定量评估的试剂和套件
    • 生物标记类型：BNP 和 NT-proBNP 生物标记在心臟衰竭诊断和管理中的广泛采用
    • 最终用户：实验室测试设施中心臟标记物的关键使用
    • 适应症：心臟标记在郁血性的潜在应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章心臟标记市场：副产品

  • 装置
    • 化学冷光
    • 酵素连结免疫吸附试验
    • 层析法
    • 萤光
  • 试剂和套件

第 7 章按生物标记物类型分類的心臟标记物市场

  • BNP 或 NT-ProBNP
  • CK-MB
  • Hs-CRP
  • 肌红蛋白
  • 肌钙蛋白 I 和 T

第八章心臟标记物市场：依最终用户分类

  • 实验室测试设施
  • 就地检验设施

第九章按适应症分類的心臟标记市场

  • 郁血性心臟衰竭
  • 心肌梗塞

第10章美洲心臟标记物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太心臟标记物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲心臟标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 迈瑞推出新检测方法，扩大心臟生物标记产品组合
    • AUDIT MicroControls, Inc. 为罗氏系统推出线性 FLQ 心臟标记
    • Cipla 推出可诊断多种健康状况的设备
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Aehealth Limited
  • Becton, Dickinson and Company
  • BG Medicine Inc.
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Danaher Corporation
  • DiaSorin SPA
  • HyTest Ltd.
  • LSI Medience Corporation
  • PerkinElmer Inc.
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
Product Code: MRR-034230D3E2D1

The Cardiac Marker Market was valued at USD 3.81 billion in 2023, expected to reach USD 4.16 billion in 2024, and is projected to grow at a CAGR of 9.71%, to USD 7.29 billion by 2030.

Cardiac markers are biomolecules released into the bloodstream when the heart is damaged or stressed, crucial in diagnosing and managing cardiac conditions. The necessity for cardiac markers stems from their critical role in early diagnosis and timely intervention of cardiovascular diseases, which remain a leading cause of mortality worldwide. These markers facilitate efficient risk stratification, monitoring, and management of diseases like myocardial infarction and heart failure. They are routinely applied in hospital emergency departments, cardiac care units, and diagnostic laboratories. The end-use scope spans across hospitals, diagnostic labs, ambulatory care centers, and research institutes. Market growth is influenced by the increasing prevalence of cardiovascular diseases, advancements in biomarker technology, and heightened public awareness toward preventive healthcare. The shift towards point-of-care testing and precision medicine presents significant opportunities, especially in emerging markets with rising healthcare investments. To leverage these opportunities, businesses should focus on developing rapid, accurate testing kits and integrating AI for enhanced data interpretation. However, market growth is challenged by factors such as regulatory complexities, high costs of sophisticated biomarker tests, and a lack of standardized protocols among laboratories. Innovating in areas like combining genetic profiling with biomarker analysis and expanding biomarker discovery through big data and machine learning could drive business growth. Companies should also explore collaborations with tech firms for automated testing solutions. The nature of the market is dynamic, involving continuous advancements in diagnostic capabilities and a high level of competition due to consistent technological progress. Industry stakeholders are recommended to invest in R&D, form strategic partnerships, and address the cost-effectiveness of diagnostic solutions to sustain competitive advantage and fulfill the growing demand for improved cardiac marker testing.

KEY MARKET STATISTICS
Base Year [2023] USD 3.81 billion
Estimated Year [2024] USD 4.16 billion
Forecast Year [2030] USD 7.29 billion
CAGR (%) 9.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Marker Market

The Cardiac Marker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing occurrence of cardiovascular diseases
    • Accessibility to a large variety of reagents and kits for cardiac biomarkers
    • Improved healthcare infrastructure and spending across economies
  • Market Restraints
    • High prices associated with cardiovascular procedures and solutions
  • Market Opportunities
    • Ongoing advancements in cardiac markers
    • Persistent improvement in the essence of point-of-care diagnostic solution
  • Market Challenges
    • Stringent regulations and approvals for cardiac markers

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Marker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Marker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Marker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Marker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Marker Market

A detailed market share analysis in the Cardiac Marker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Marker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Marker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Marker Market

A strategic analysis of the Cardiac Marker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments and Reagents & Kits. The Instruments is further studied across Chemiluminescence, ELISA, Immunochromatography, and Immunofluorescence.
  • Based on Biomarker Type, market is studied across BNP Or NT-ProBNP, CK-MB, Hs-CRP, Myoglobin, and Troponin I & T.
  • Based on End-User, market is studied across Laboratory Testing Facilities and Point of Care Testing Facilities.
  • Based on Indication, market is studied across Congestive Heart Failure and Myocardial Infarction.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing occurrence of cardiovascular diseases
      • 5.1.1.2. Accessibility to a large variety of reagents and kits for cardiac biomarkers
      • 5.1.1.3. Improved healthcare infrastructure and spending across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High prices associated with cardiovascular procedures and solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in cardiac markers
      • 5.1.3.2. Persistent improvement in the essence of point-of-care diagnostic solution
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and approvals for cardiac markers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins
    • 5.2.2. Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure
    • 5.2.3. End-User: Significant utilization of cardiac marker in laboratory testing facilities
    • 5.2.4. Indication: Potential adoption of cardiac markers in congestive heart failure situations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Marker Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
    • 6.2.1. Chemiluminescence
    • 6.2.2. ELISA
    • 6.2.3. Immunochromatography
    • 6.2.4. Immunofluorescence
  • 6.3. Reagents & Kits

7. Cardiac Marker Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. BNP Or NT-ProBNP
  • 7.3. CK-MB
  • 7.4. Hs-CRP
  • 7.5. Myoglobin
  • 7.6. Troponin I & T

8. Cardiac Marker Market, by End-User

  • 8.1. Introduction
  • 8.2. Laboratory Testing Facilities
  • 8.3. Point of Care Testing Facilities

9. Cardiac Marker Market, by Indication

  • 9.1. Introduction
  • 9.2. Congestive Heart Failure
  • 9.3. Myocardial Infarction

10. Americas Cardiac Marker Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cardiac Marker Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cardiac Marker Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays
    • 13.3.2. AUDIT MicroControls, Inc. Announces Linearity FLQ Cardiac Markers for Roche Systems
    • 13.3.3. Cipla Launches Diagnostic Device For Multiple Health Conditions
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aehealth Limited
  • 3. Becton, Dickinson and Company
  • 4. BG Medicine Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Biomerieux SA
  • 7. Danaher Corporation
  • 8. DiaSorin S.P.A.
  • 9. HyTest Ltd.
  • 10. LSI Medience Corporation
  • 11. PerkinElmer Inc.
  • 12. QuidelOrtho Corporation
  • 13. Randox Laboratories Ltd.
  • 14. Roche Diagnostics Ltd.
  • 15. Siemens Healthineers AG
  • 16. Thermo Fisher Scientific Inc.
  • 17. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. CARDIAC MARKER MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC MARKER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIAC MARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CARDIAC MARKER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CARDIAC MARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC MARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIAC MARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC MARKER MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC MARKER MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC MARKER MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC MARKER MARKET SIZE, BY IMMUNOCHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC MARKER MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC MARKER MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC MARKER MARKET SIZE, BY BNP OR NT-PROBNP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC MARKER MARKET SIZE, BY CK-MB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC MARKER MARKET SIZE, BY HS-CRP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC MARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC MARKER MARKET SIZE, BY TROPONIN I & T, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC MARKER MARKET SIZE, BY LABORATORY TESTING FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC MARKER MARKET SIZE, BY POINT OF CARE TESTING FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC MARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC MARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. CARDIAC MARKER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. CARDIAC MARKER MARKET, FPNV POSITIONING MATRIX, 2023